Biopharma

Patrick Speedie, Co-Founder & Co-CEO of IN-PART, explores why a global approach is needed for the best science to prosper and the lessons industry can take from the Covid-19 pandemic.    The Covid-19 pandemic unequivocally demonstrated the power of industry-academia collaboration, with the fastest ever development, testing and approval of a life-saving vaccine. We saw colleagues […]

This is the latest episode of the free DDW narrated podcast, “Important therapies for the future of immunotherapy”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Improving quality control for CAR T cell therapies”, and “The importance of LAG-3 to the future of immunotherapy”. The […]

This is the latest episode of the free DDW narrated podcast, “Overcoming different barriers in drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Addressing the challenge of salt forms in drug discovery”, “A different approach: reimagining biology”, and “Women in Discovery: championing female […]

The pharmaceutical industry continues to maintain strong levels of public trust and favourability in the UK, according to data from the Association of the British Pharmaceutical Industry (ABPI). Opinions showed consistent recognition of the sector’s support for the NHS, with 67% of respondents saying the industry is committed to developing new medicines to meet patient […]

This is the latest episode of the free DDW narrated podcast, “A business case for drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “A deal in the making”, “Why project management holds the key to efficient drug development”, and “Transcending expectations for cell & […]

This is the latest episode of the free DDW narrated podcast, “Challenges and tactics for transformative drug development”. It covers two articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Balancing speed and quality in CLD for faster drug development”, and “Sitting down with BridgeBio Pharma”. In the first article, Soojin Han, Chief Technical Lead […]

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Clarivate’s ‘Biopharma Dealmaking in 2023’ report examines how pharma companies are replenishing their pipelines as many face a steep patent cliff. The report combines data and insights from BioWorld, Cortellis Deals […]

The first full day of SLAS2023 offered plenty for visitors to see and learn from. Here are some of the biggest launches that were on offer throughout day one of the show. PerkinElmer targets screening methods End-to-end solutions provider PerkinElmer launched two new products at the show targeting both high high-throughput screening (HTS) applications and […]

DDW Editor Reece Armstrong speaks to Peter Walters, Director Advanced Therapies, CRB, and Grace Linton, Director Process Architecture, CRB about automation within laboratory settings and its effect on the pharmaceutical industry. RA: How are labs utilising automated systems in regard to personalised medicines? PW: Process development and pilot labs are seeing flexible, adaptable, and automated […]

This is the latest episode of the free DDW podcast. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Why synthetic biology is the next big thing for biopharma” and “Collaborative spirit helps drive innovation”. ‘Can synthetic biology save us?’ and ‘Synthetic biology can benefit us […]

DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year.   The Market After over two years of the Covid-19 pandemic, 2022 year was somewhat of a return to normal for both the world at […]

Kevin Hemphill, R&D Manager at PerkinElmer’s Horizon Discovery explores how base editing has emerged as an attractive gene editing option for researchers wanting to develop stem cell-based therapies.   Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential for applications across the healthcare […]

Listen to this article on the DDW Podcast: ‘Can synthetic biology save us?’ and ‘synthetic biology can benefit us all’, are just some of the headlines this emerging scientific field has recently elicited. Lu Rahman speaks to Dr Emily Leproust, Founder and CEO of Twist Biopharma, about the potential that synthetic biology holds within the drug discovery sector.  “Most […]

Professor Michael Butler, head of the National Institute for Bioprocessing Research and Training (NIBRT) Cell Technology Group (CTG), explains that the characterisation and analysis of glycans is important for the biopharma sector as it can help in the development of therapeutic agents such as monoclonal antibodies and other recombinant proteins. These are used in therapies […]

Following a decade of solid groundwork to modernise regulatory information management in life sciences, leading companies have now shifted their focus to how they might exploit this new digital landscape – to transform process management; improve data exchange with the enterprise at large; revisit organisational structures and roles, and enable greater patient access to information. […]

This 24-page DDW eBook, sponsored by Emulate Bio, contains exclusive insight from industry experts on: How microfluidics is fuelling innovation in drug discovery A detailed look at the organ-on-a-chip sector How human tissue chips are helping advance our understanding of biology This guide is free of charge and you can access here